Tectonic Therapeutic, Inc.
corporate_fare Company Profile
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for TECX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for TECX spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Tectonic 10-Q: $21.3M Q3 Loss, $234.7M Cash, $22.3M Net ATM Proceeds
- Tectonic Posts Q3 Loss of $21.3M, Cash Runway Into Q1 2029, APEX Data Due January 2027
- Tectonic's TX2100 Shows Favorable Phase 1a Safety, Wins FDA Fast Track for HHT
- Cronos Network Restarts After $74M Tectonic Exploit; Only $6M Bridged Out
- Cronos Halts After $75M Tectonic Exploit via TONIC Price Manipulation
Financial Snapshot
Short Interest & Short Volume
13.66 days to coverFINRA reported short interest of 2,375,596 shares in TECX as of the October 30, 2026 settlement, a 6.8% increase from the prior period — about 13.7 days to cover at its recent average daily volume. On November 20, 2026, 70.6% of TECX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.